<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413632</url>
  </required_header>
  <id_info>
    <org_study_id>2014/50</org_study_id>
    <secondary_id>2014-A01358-39</secondary_id>
    <nct_id>NCT02413632</nct_id>
  </id_info>
  <brief_title>Screening Strategy for Asymptomatic Sexually Transmitted Infections (STI) in a Cohort of HIV Outpatients Men Who Have Sex With Men (DRIVER)</brief_title>
  <acronym>DRIVER</acronym>
  <official_title>Asymptomatic Sexually Transmitted Infections (STI) : Comparison of Two Screening Strategies Routine Screening Versus Screening as Reported by the Risks Taken by the Patient, in a Cohort of HIV Outpatients Men Who Have Sex With Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint-Louis Hospital, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bicetre Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hotel Dieu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Franco-Britannique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Mutualiste Montsouris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Lagny Marne la Vallée</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Raymond Poincaré</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Argenteuil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Ambroise Paré Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of two screening strategies of asymptomatic sexually transmitted infections :
      routine screening versus screening as reported by the risks taken by the patient, in a
      cohort of HIV outpatients men who have sex with men. The aim of this study will be create
      and validate a simple tool for clinicians. A digital tool will be developed will allowed
      empowerment of HIV-positive men who have sex with men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objectives are :

      create and validate a risk score for STIs (DRIVER score) in a population of HIV-positive men
      who have sex with men (MSM).

      determine the prevalence of asymptomatic STIs in a population of HIV-positive MSM

      Secondary objectives are :

      compare 2 screening strategies regarding STIs in HIV-positive MSM (systematic screening vs
      screening according to self-declared risk factors) conduct a cost-efficiency analysis of
      both strategies evaluate patients' knowledge of STIs develop a DRIVER digital tool that will
      be made available to patients on websites, mobile apps…

      Position of the problem :

      Over the past 15 years, a resurgence of symptomatic STIs has been observed at both at the
      global and at the local (French) level. This has been true for gonorrhea since 2008, for
      syphilis since 2000 and for lymphogranuloma venereum since 2003. The epidemiology of
      asymptomatic STIs has not been studied as thoroughly but asymptomatic carriage of Neisseria
      gonorrhoeae and Chlamydia trachomatis as well as latent syphilis account for at least half
      of cases declared in the past few years. The population of HIV-positive MSM is the
      demographic category with the highest rates of STIs. In addition, risky sexual attitudes are
      on the rise in the MSM population in general (in 2010, the French RESIST Network reported
      that condom use during anal penetrations between males had dropped from 49% in 2008 to 37%
      in 2010).

      Screening practices are currently center- and healthcare-provider dependant. Study will
      allow a comparison of screening practices thanks to a score that will be built, validated
      and made available to clinicians and patients.

      Type of study : Prospective, non randomized, multicentric and cross-sectional Timeline :
      Study duration : 18 months Beginning of study : March 2015
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sexually Transmitted Infections risk score in men HIV positive</measure>
    <time_frame>6 months</time_frame>
    <description>Construction of a STI risk score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost-efficacy of a targeted screening versus universal screening</measure>
    <time_frame>12 months</time_frame>
    <description>conduct a cost-efficiency analysis of both strategies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients' knowledge of STIs evaluated by a Sexually Transmitted Disease Knowledge Questionnaire (STD-KQ)</measure>
    <time_frame>3 months</time_frame>
    <description>patients' knowledge of STIs will be evaluate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prevalence of asymptomatic STIs in a population of HIV-positive MSM</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>First period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>creation of a STIs score risk
pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>validation of a STIs score risk
pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>creation of a STIs score risk</intervention_name>
    <description>4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)</description>
    <arm_group_label>First period</arm_group_label>
    <other_name>First period</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>validation of a STIs score risk</intervention_name>
    <description>DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)</description>
    <arm_group_label>Second period</arm_group_label>
    <other_name>Second period</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive outpatients

          -  Men who have sex with men

          -  Speaking, literate french

          -  Having a french health insurance or an equivalent

          -  Asymptomatic for a STI the appointment day

        Exclusion Criteria:

          -  Men who never had sex with men

          -  Protected adults (adults under guardianship)

          -  Have a STI symptom ( anal discharge, urethritis, proctitis, chancre, rush)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David ZUCMAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Svetlane DIMI, MD</last_name>
    <phone>+33146252093</phone>
    <email>s.akpe@hopital-foch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Hauts de Seine</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Zucman, MD</last_name>
      <phone>+331 46 25 20 93</phone>
      <email>d.zucman@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>David Zucman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Duracinsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 2, 2016</lastchanged_date>
  <firstreceived_date>March 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-positive MSM (men who have sex with men)</keyword>
  <keyword>asymptomatic sexually transmitted infections</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
